A5175: A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICAC

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 假设：每天一次和每天两次的三药抗逆转录病毒(ARV)方案在资源有限的情况下对CD4+细胞计数为300个/mm3的HIV-1感染者提供了类似的ARV益处。 在资源有限的情况下，每天给药一次的含有蛋白酶抑制剂(PI)的三药抗逆转录病毒方案与每天两次给药的含有非核分裂逆转录酶(NNRTI)的三药抗逆转录病毒方案相比，在资源有限的情况下为CD4+细胞计数为300cell/mm3的HIV-1感染者提供了类似的抗逆转录病毒益处。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypotheses: Three-drug antiretroviral (ARV) regimens administered once-daily and twice-daily provide similar ARV benefit in resource-limited settings for HIV-1- infected persons with CD4+ cell counts <300 cells/mm3. A three-drug ARV regimen containing a protease inhibitor (PI), administered once-daily, provides similar ARV benefit in resource-limited settings for HIV-1-infected persons with CD4+ cell counts <300 cell/mm3 as compared with a three-drug ARV regimen administered twice daily that contains an non-nucleosis reverse transcriptase (NNRTI).